You are here: Home » Current Affairs » News » Health
Business Standard

How French drugmaker Sanofi's setback could lead to better dengue vaccines

Dengvaxia uses a widely effective yellow fever virus vaccine as its genetic backbone. To induce an immune response to dengue, certain yellow fever genes were swapped out for dengue genes

Reuters  |  Chicago 

New dengue vaccines being developed by Takeda Pharmaceuticals Co Ltd and U.S. government scientists are poised to provide a safer alternative to Sanofi's Dengvaxia, according to vaccine experts, because they already take into account some of the issues that sidelined the product last year. Sanofi revealed in November that Dengvaxia - the world's first dengue vaccine - might increase the risk of severe disease in people who had never been exposed to the virus. The news prompted an uproar in the Philippines, where more than 800,000 school-age children had been ...

This article is no longer available in our repository.

There could be multiple reasons for this.

First Published: Mon, January 29 2018. 19:04 IST
RECOMMENDED FOR YOU